Amedisys Carves Out New Highs on Oppenheimer's Latest Hike

Evolus scored a key approval in Canada for its Botox biosimilar

Managing Editor
Aug 17, 2018 at 2:39 PM
facebook X logo linkedin


Stocks are mixed on the final day of the week, but the Dow and S&P 500 are heading toward weekly wins. Looking at individual names, drug stock Acer Therapeutics Inc (NASDAQ:ACER), health care company Amedisys Inc (NASDAQ:AMED), and biotech name Evolus Inc (NASDAQ:EOLS) are all trading higher today. Here's a closer look at what's moving shares of ACER, AMED, and EOLS.

Upgrade Puts ACER Stock Near Two-Year High

Acer Therapeutics stock is up 10.7% to trade at $29.05 -- one of the better stocks on the Nasdaq today -- after Raymond James upgraded the pharma name to "strong buy" from "outperform," while raising its price target to $46 from $31. The new price target represents territory Acer stock has not traded in since September 2016.

ACER is just a chip-shot from its two-year high of $30.23, nabbed last Friday. The equity has more than tripled in the last 12 months, and handily doubled in 2018. Amidst this broader surge, the shares' 200-day moving average contained an early August sell-off. 

Fresh Record Highs for AMED After Price-Target Hike

Amedisys stock is up 1.7% to trade at $119.50, and earlier hit a new record high of $120.30, after receiving a price-target hike to $125 from $103 at Oppenheimer. This bull note follows Oppenheimer's previous price-target boost to $103 from $85, issued as recently as July 31.

AMED has carved out a channel of higher highs and lows all year, with an Aug. 1 bull gap propelling the stock well north of support at its 30-day moving average. The shares boast a year-over-year lead of 137%, and are currently on pace for an eighth consecutive winning month. 

EOLS Rallies on Canadian Regulator's Nod

Last but not least, Evolus stock is up 6.5% to trade at $19.98, after Health Canada granted early approval to the company's Botox rival, DWP-450. Evolus expects the drug to launch in the U.S. by the spring of 2019, and receive approval from the European Union (EU) by the first half of 2019.

Since a mid-July bear gap, the equity has been trading sideways between the $18 and $21 levels. Today's rally places EOLS in the middle of this range -- and just above that familiar ceiling at $21 is another potential hurdle at $22.67, which represents a 50% retracement of the equity's all-time closing low and high. Plus, $24 marks a double of the drug company's February initial public offering (IPO) price.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI